摘要
目的:观察长春瑞滨联合顺铂(NP方案)治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副作用。方法:42例经病理或细胞学诊断为非小细胞肺癌患者,其中腺癌4例,鳞癌38例。TNM分期Ⅲ期23例,Ⅳ期19例。所有病例均为初治。采用国产长春瑞滨25mg/m^2,第1、8天静滴;顺铂(DDP)30mg/m^2第1~3天静滴,28d为一个周期。治疗至少2个周期后进行疗效和毒性反应评价。结果:完全缓解(CR)3例,部分缓解(PR)15例,稳定(SD)16例,进展(PD)8例,总有效率(CR+PR)为42.9%。主要毒副反应为白细胞减少及胃肠道反应,其Ⅲ、Ⅳ度白细胞下降占11.9%,呕吐发生率为54.7%。结论:长春瑞滨联合顺铂(NP方案)治疗晚期NSCLC疗效确切,毒副反应可耐受。
Objective: To observe the efficacy and toxicity of vinorelbine combined with cisplatin (NP regimen) in the treatment of advanced non-small-cell lung cancer(NSCLC). Methods:42 patients with advanced NSCLC were confirmed by pathology or cytology. There were 4 patients with lung adenocarcinoma,38 with squamous carcinoma. 23 patients had stage Ⅲ diease and 19 patients had stage Ⅳ. All patients had no prior chemotherapy. NVB were used 25 mg per centiare on days 1 and days 8;DDP were used 30 mg per centiare on days 1 to days 3. A Period includes 28 days. to evaluate the efficacy and toxicity after 2 periods at least. Results:Complete response was observed in 3 patients and partial response was observed in 15 patients. The overall response rate was 42.9%. The main tocicity was leucopenia and vomiting. The dose limiting toxicity was neutropenia that was observed in 83.3% of the patients(11.9% in grades Ⅲ and Ⅳ). About 54.7% of the patients was observed vomitting. Conclusions: The results indicate NP regimen for advanced NSCLC is promise,and the toxicities are tolerable.
出处
《实用临床医学(江西)》
CAS
2006年第9期32-34,37,共4页
Practical Clinical Medicine
关键词
非小细胞肺癌
长春瑞滨
顺铂
化疗
non-all-cell lung cancer
vinorelbine
cisplatin
chemotherapy